FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia

The FDA ' s approval is for the first drug targeting FLT3 mutations in AML.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news